AbbVie acquired Allergan plc for $63 billion, a transaction completed in May 2020, structured as cash-and-stock.
Allergan plc operates in Medical aesthetics, neuroscience, eye care & immunology, is based in Dublin, Ireland. AbbVie's largest acquisition to date. Allergan brought its global aesthetics franchise led by Botox, plus branded therapeutics across neuroscience, eye care and women's health. The deal was structured under Irish Takeover Rules; Allergan holders received a mix of cash and AbbVie stock. It diversified AbbVie's revenue base ahead of Humira's loss of exclusivity.
Provides immediate scale and profitability to AbbVie's growth platform (excluding Humira) and meaningfully diversifies revenue while sustaining investment in the innovative pipeline.
AbbVie targeted more than $2 billion of annual pre-tax synergies by year three.
This is a transformational transaction for both companies and achieves unique and complementary strategic objectives.Richard A. Gonzalez, Chairman and CEO, AbbVie
Advisory firms were not disclosed for this transaction.